Health-related quality of life in the early-access phase IIIb study of trifluridine/tipiracil in pretreated metastatic colorectal cancer (mCRC): Results from PRECONNECT study.

摘要: 638Background: Pivotal RECOURSE trial assessed efficacy and safety of trifluridine/tipiracil (FTD/TPI) in mCRC patients (pts) without collecting QoL data. Here we describe a preliminary analysis pts treated with FTD/TPI the ongoing phase 3b PRECONNECT study (NCT03306394). Methods: Eligible had histologically previously available therapies an ECOG-PS 0/1. Pts received (35 mg/m2 twice daily) orally on days 1–5 8–12 each 28-day cycle. were at baseline, every 4 weeks discontinuation. was measured EORTC QLQ-C30, EQ-5D index VAS questionnaires. Utility score based values from Germany, UK Spain. For clinical relevance using 10 point threshold. Changes utility deemed clinically relevant if ≥ 9 7, respectively. Only results where 10% initial cohort completed questionnaires assessed, corresponding to 7 c...